253 related articles for article (PubMed ID: 10186468)
21. Effects of robotic treadmill training on functional mobility, walking capacity, motor symptoms and quality of life in ambulatory patients with Parkinson's disease: a preliminary prospective longitudinal study.
Paker N; Bugdayci D; Goksenoglu G; Sen A; Kesiktas N
NeuroRehabilitation; 2013; 33(2):323-8. PubMed ID: 23949054
[TBL] [Abstract][Full Text] [Related]
22. Prospective study on cost-effectiveness of home-based motor assessment in Parkinson's disease.
Cubo E; Mariscal N; Solano B; Becerra V; Armesto D; Calvo S; Arribas J; Seco J; Martinez A; Zorrilla L; Heldman D
J Telemed Telecare; 2017 Feb; 23(2):328-338. PubMed ID: 27000142
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
[TBL] [Abstract][Full Text] [Related]
24. Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis.
Martinez-Martín P; Rodriguez-Blazquez C; Paz S; Forjaz MJ; Frades-Payo B; Cubo E; de Pedro-Cuesta J; Lizán L;
PLoS One; 2015; 10(12):e0145310. PubMed ID: 26698860
[TBL] [Abstract][Full Text] [Related]
25. The current and projected economic burden of Parkinson's disease in the United States.
Kowal SL; Dall TM; Chakrabarti R; Storm MV; Jain A
Mov Disord; 2013 Mar; 28(3):311-8. PubMed ID: 23436720
[TBL] [Abstract][Full Text] [Related]
26. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
Santos-García D; de la Fuente-Fernández R
J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
[TBL] [Abstract][Full Text] [Related]
27. Cabergoline versus levodopa monotherapy: a decision analysis.
Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
29. Real life evaluation of safinamide effectiveness in Parkinson's disease.
Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
[TBL] [Abstract][Full Text] [Related]
30. Costs of Parkinson's disease in eastern Europe: a Czech cohort study.
Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E
Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915
[TBL] [Abstract][Full Text] [Related]
31. Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK.
Weir S; Samnaliev M; Kuo TC; Tierney TS; Walleser Autiero S; Taylor RS; Schrag A
Mov Disord; 2018 Jul; 33(6):974-981. PubMed ID: 29603405
[TBL] [Abstract][Full Text] [Related]
32. [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease].
Dengler I; Leukel N; Meuser T; Jost WH
Nervenarzt; 2006 Oct; 77(10):1204-9. PubMed ID: 17004081
[TBL] [Abstract][Full Text] [Related]
33. Costs of illness in a Russian cohort of patients with Parkinson's disease.
Winter Y; von Campenhausen S; Popov G; Reese JP; Klotsche J; Bötzel K; Gusev E; Oertel WH; Dodel R; Guekht A
Pharmacoeconomics; 2009; 27(7):571-84. PubMed ID: 19663528
[TBL] [Abstract][Full Text] [Related]
34. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.
LePen C; Wait S; Moutard-Martin F; Dujardin M; Ziégler M
Pharmacoeconomics; 1999 Jul; 16(1):59-69. PubMed ID: 10539122
[TBL] [Abstract][Full Text] [Related]
35. [Direct medical costs of Parkinson's disease by Hoehn and Yahr severity in Japan: An analysis of administrative claims data].
Baba K; Naoi I; Shibahara H; Inoue S; Aino H
Rinsho Shinkeigaku; 2022 Jul; 62(7):524-531. PubMed ID: 35753784
[TBL] [Abstract][Full Text] [Related]
36. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
37. A review of the health-related quality of life and economic impact of Parkinson's disease.
Dowding CH; Shenton CL; Salek SS
Drugs Aging; 2006; 23(9):693-721. PubMed ID: 17020395
[TBL] [Abstract][Full Text] [Related]
38. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease.
Bach JP; Riedel O; Klotsche J; Spottke A; Dodel R; Wittchen HU
J Neurol Sci; 2012 Mar; 314(1-2):41-7. PubMed ID: 22133477
[TBL] [Abstract][Full Text] [Related]
39. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.
Fraix V; Houeto JL; Lagrange C; Le Pen C; Krystkowiak P; Guehl D; Ardouin C; Welter ML; Maurel F; Defebvre L; Rougier A; Benabid AL; Mesnage V; Ligier M; Blond S; Burbaud P; Bioulac B; Destée A; Cornu P; Pollak P;
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):443-9. PubMed ID: 16543519
[TBL] [Abstract][Full Text] [Related]
40. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
